For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Small and emerging biotechs in the United States and Europe have long been wary of trying to enter the Chinese market, despite its vast potential. They’ve shied away due to changing regulatory and reimbursement policies, unreliable intellectual property protections, and fear that the Chinese government may favor domestic firms. But things have changed, and companies don’t need to be hesitant anymore.
Since 2015, a slew of economic and regulatory reforms have improved the Chinese market dynamics for foreign companies. In 2018, the Chinese State Council eliminated tariffs (of 6% to 10%) on all imported cancer drugs and slashed the value-added tax on them from 17% to 3%. In 2020, 28 new drugs from nondomestic companies were approved by the National Medical Products Administration (NMPA), faster and more dependably than before. In May 2021, China was reelected for a three-year term to the management committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, further aligning it with international regulatory standards.
Large international pharma companies often include China because of its market size, and many put it near the top of the list when sequencing global marketing submissions. But how can small and emerging foreign companies with limited resources gain a foothold in the Chinese market? Here are five approaches that help.
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
India, the Generic Manufacturing Powerhouse, Biosimilar Next?
Jul 21, 2021
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Pharma Talk Radio: Building a Successful Relationship with your Development Partner
Oct 5, 2021
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
3 steps for making your CRO relationships more successful
Jul 29, 2021
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Case Study Marketing Authorization Transfer
Nov 25, 2021
4 Insights on decentralized trials for biotechs
Jul 1, 2021